Abstract:Deletions of regions at 13q14 have been detected by various genetic approaches in human cancers including prostate cancer. Several studies have defined one region of loss of heterozygosity (LOH) at 13q14 that seems to reside in a DNA segment of 7.1 cM between genetic markers D13S263 and D13S153. To define the smallest region of overlap (SRO) for deletion at 13q14, we first applied tissue microdissection and multiplex PCR to detect homozygous deletion and/or hemizygous deletion at 13q14 in 134 prostate cancer specimens from 114 patients. We detected deletions at markers D13S1227, D13S1272, and A005O48 in 13 (10%) of these tumor specimens. Of the 13 tumors with deletions, 12 were either poorly differentiated primary tumors or metastases of prostate cancer. To fine-map the deletion region, we then constructed a high-resolution YAC/BAC/STS/EST physical map based on experimental and database analyses. Several markers encompassing the deletion region were analyzed for homozygous deletion and/or hemizygous deletion in 61 cell lines/xenografts derived from human cancers of the prostate, breast, ovary, endometrium, cervix, and bladder, and a region of deletion was defined by duplex PCR assay between markers A005X38 and WI-7773. We also analyzed LOH at 13q14 in the 61 cell lines/xenografts using the homozygosity mapping of deletion approach and 26 microsatellite markers. We found 24 (39%) of the cell lines/xenografts to show LOH at 13q14 and defined a region of LOH by markers M1 and M5. Combination of homozygous or hemizygous deletion and LOH results defined the SRO for deletion to be an 800-kb DNA interval between A005X38 and M5. There are six known genes located in or close to the SRO for deletion. This region of deletion is at least 2 Mb centromeric to the RB1 tumor-suppressor gene and the leukemia-associated genes 1 and 2, each of which is located at 13q14. These data suggest that the 800-kb DNA segment with deletion contains a gene whose deletion may be important for the development of prostate and other cancers. This study also provides a framework for the fine-mapping, cloning, and identification of a novel tumor-suppressor gene at 13q14.

Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression

Differentially expressed genes in androgen-dependent and -independent prostate carcinomas

Part-1: A Novel Human Prostate-Specific, Androgen-Regulated Gene That Maps To Chromosome 5q12

Prostate Cancer Risk Locus at 8q24 As a Regulatory Hub by Physical Interactions with Multiple Genomic Loci Across the Genome.

Advances in Brief PART-1 : A Novel Human Prostate-specific , Androgen-regulated Gene that Maps to Chromosome 5 q 121

Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus

Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin

Data from Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis

FOXO1A is a Candidate for the 13q14 Tumor Suppressor Gene Inhibiting Androgen Receptor Signaling in Prostate Cancer.

Gene expression analysis of prostate cancers

Gene-environment Analysis on Association of Chromosome 8q24 and Chromosome 17q24 with Prostate Cancer in Chinese Population

An 800-kb region of deletion at 13q14 in human prostate and other carcinomas

Gene Expression Profiling Identifies Clinically Relevant Subtypes Of Prostate Cancer

The Program of Androgen-Responsive Genes in Neoplastic Prostate Epithelium.

UQCRB and LBH are correlated with Gleason score progression in prostate cancer: Spatial transcriptomics and experimental validation

Identification of a Novel Gene with Increasing Rate of Suppression in High Grade Prostate Cancers

A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 As Novel Aggressive Prostate Cancer Susceptibility Genes

Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas.

Gene expression alterations in human prostate cancer.

Identification of a prostate-specific G-protein coupled receptor in prostate cancer

Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis